Thank you for subscribing!
Finfeed Archived Sep 09, 2019
Imagion’s shares received a boost with strong trading throughout the morning resulting in an increase from the previous day’s close of 4.1 cents to 4.5 cents just before midday.
Imagion Biosystems (ASX:IBX) advised the market of early-stage evidence that the technology could have applications in improving magnetic resonance imaging (MRIs).
Finfeed Archived Aug 28, 2019
Imagion Biosystems (ASX:IBX) CEO, Robert Proulx speaks to Finfeed's Jonathan Jackson about the company's important work in early stage cancer detection.
Next Investors Archived Aug 14, 2019
MagSense is a unique, non-invasive, patent protected technology that fits into myriad addressable cancer diagnostic markets collectively worth $166 billion dollars and growing at 7% annually.
Get expert stock analysis direct in your inbox
Finfeed Archived Aug 07, 2019
Rhythm Biosciences Ltd (ASX:RHY) is continuing to develop its global, low-cost, lifesaving blood test for the detection of colorectal cancer, ColoSTAT®.
Finfeed Archived Aug 05, 2019
Today, as a man who writes a lot about medical cannabis and related listed companies, my interest is always piqued by medical cannabis based human interest stories.
Next Investors Archived Jul 25, 2019
Imugene Limited (ASX:IMU) has negotiated to acquire a worldwide exclusive license to a promising OV developed at LA’s City of Hope Hospital.
Finfeed Archived May 23, 2019
Drug delivery company Invion Limited (ASX:IVX) is leading the way in developing PhotosoftTM technology for the treatment of a range of cancers.
Next Investors Archived May 14, 2019
What if there was a cost effective way for patients to assess their cancer risk and seek treatment? There is. Genetic Technologies (ASX:GTG; NASDAQ:GENE).
Join Our Mailing List
